黄晓啊,等.普拉梭菌与肠道疾病关系的研究进展 dysbiosis in patients with ulcerative colitis irritable bowel syndrome patients: a molecular■间行评价 ut2014;63:1275-1283[PMID:24021287DOl approach. Clin Exp Gastroenterol 2015; 8: 309-325 F. prausnitziif PMD26673000DO:10.2147/CEG58999为人类最丰富的 24 Varela E, Manichanh C, Gallart M, Torrejon A32 Miquel S, Martin r, Lashermes a, Gillet M,肠道共生菌之 Borruel N, Casellas F, Guarner F, Antolin M Meleine M, Gelot A, Eschalier A, Ardid D, ,其在肠道疾 Colonisation by Faecalibacterium prausnitzii and Bermudez.Humaran Lg, Sokol h, Thomas m,病中所起的作用 naintenance of clinical remission in patients with Theodorou V, Langella P, Carvalho FA.Anti.越来越引起人们 ulcerative colitis. Aliment Pharmacol Trer 2013: 38 nociceptive effect of Faecalibacterium prausnitzii 151-161|PMID:23725320DO:10.111apt12365」 in non-inflammatory IBS-like models. Sci Rep prausnizln的作用 Cao Y, Shen J, Ran ZH. Association between 20166:19399PMD:26775847DO:10.1038/机制、抗炎有效 Faecalibacterium prausnitzii Reduction and 成分以及与肠道 nflammatory Bowel Disease: A Meta-Analysis3 opez-Siles M, Martinez-Medina M, Suris-valls的关的研 and Systematic Review of the Literature Gastroenterol Res Pract 2014; 2014: 872725 [PMID: R, Aldeguer X, Sabat-Mir M, Duncan SH, Flin系统的综逑,有 HJ, Garcia-Gil LJ Changes in the Abundance of理论和实用价值 24799893DO:10.1155/2014/872725 Faecalibacterium prausnitzii Phylogroups I and II 26 Hansen R, Russell RK, Reiff C Louis P, Mclntosh in the Intestinal Mucosa of Inflammate F, Berry SH, Mukhopadhya I, Bisset WM, Barclay isease and Patients with Colorectal AR, Bishop ), Flynn DM, McGrogan P, Loganathan Inflamm Bowel Dis 2016: 22: 28-41 [PMID S, Mahdi G, Flint H, El-Omar EM, Hold GL DO:10.1097/MIB000000009g Microbiota of de-novo pediatric IBD: increased 34 Balamurugan R, Rajendiran E, George S, Samuel Faecalibacterium prausnitzii and reduced bacterial GV, Ramakrishna BS Real-time polymerase diversity in Crohns but not in ulcerative colitis chain reaction quantification of specific A Gastroenterol 2012: 107: 1913-1922 [PMID: butyrate-producing bacteria, Desulfovibrio and 23044767D /aig2012335 Enterococcus faecalis in the feces of patients with 27 Yang J, Lee HR, Low K, Chatterjee S, Pimentel colorectal cancer. Gastroenterol Hepatol 2008, M. Rifaximin versus other antibiotics bacterial 23:1298-1303 IPMID:18624900DOl:10.111 primary treatment and retreatment of ba 144-1746200805490.x 35 Scanlan PD, Shanahan F, Clune Y, Collins K, O PMID:17520365DOL:10.1007/s10620007-9839-8 Sullivan GC, ORiordan M, Holmes E, Wang Y, 28 Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander Marchesi JR. Culture-independent analysis of the K, Kekkonen RA, Tims s, de vos wm. Global gut microbiota in colorectal cancer and polyposis and deep molecular analysis of microbiota Environ Microbiol 2008; 10: 789-798 [PMID natures in fecal samples from patients with 8237311DO:10.111146229202007.01503×] 141:1792-1801PMID:21820992DOl:10.1053/ Letulle S, Langella P, Corthier G, Tran Van Nhieu 1-gastro201107.043] Furet P Microbial dysbiosis in colorectal cancer 29 Duboc H, Rainteau D, Rajca S, Humbert L, CRO patients. PLos One 2011; 6: e16393 [PMID: Farabos D, Maubert M, Grondin V, Jouet P 1297998DO1:10.1371/ journal. pone.0016393 Bouhassira D, Seksik P, Sokol H, Coffin B, Sabate 37 De Palma G, Nadal I, Medina M, Donat E, Ribes- JM. Increase in fecal primary bile acids and Koninckx C, Calabuig M, Sanz Y Intestinal dysbiosis in patients with diarrhea-predominant dysbiosis and reduced oglobulin irritable bowel syndrome. Neurogastroenterol Motil coated bacteria associated with coeliac diseas 12;24:513-520,e246-e247[PMID:22356587 children. BMC Microbiol 2010: 10: 63 DOl:10.11 0181275DOl:10.1186/1471-2180-1063 pez-Siles M, Martinez.Medina M, Busquets 38 Swidsinski A, Loening-Baucke V, Verstraelen D, Sabat-Mir M, Duncan SH, Flint H, H, Osowska S, Doerffel Y Biostructure of fecal Aldeguer X, Garcia-Gil L]. Mucosa-associated microbiota in healthy subjects and patients with Faecalibacterium prausnitzii and Escherichia hronic idiopathic diarrhea. Gastroenterology 2008 coli co-abundance can distinguish Irritable 135:568-579[PMID:18570896DO:10.1053/ Bowel Syndrome and Inflammatory Bowel j-gastro.2008.04017 Disease phenotypes. Int) Med Microbiol 2014 Swidsinski A, Dorffel Y, Loening- Baucke V 304:464-475[PMD:24713205DOI:10.1016/ Theissig F, Rickert JC, Ismail M, Rau WA, j-iImn201402009 Gaschler D, Weizenegger M, Kuhn S, Schilling J, 31 Soldi S, Vasileiadis S, Uggeri F, Campanale M, DOrffel WV. Acute appendicitis is characterised torelli L, Fogli MV, Calanni F, Grimaldi M, by local invasion with Fusobacterium nucleatum/ Gasbarrini A Modulation of the gut microbiota necrophorum Gut 2011; 60: 34-40 [PMID composition by rifaximin in non-constipated 19926616DOl:10.1136/gut2009.191320 编辑:马亚娟电编:李瑞芳 +5Aishideng 2017-03-28I Volume 25 Issue 9 I黄晓丽, 等. 普拉梭菌与肠道疾病关系的研究进展 WCJD|www.wjgnet.com 815 2017-03-28|Volume 25|Issue 9| dysbiosis in patients with ulcerative colitis. Gut 2014; 63: 1275-1283 [PMID: 24021287 DOI: 10.1136/gutjnl-2013-304833] 24 Varela E, Manichanh C, Gallart M, Torrejón A, Borruel N, Casellas F, Guarner F, Antolin M. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 151-161 [PMID: 23725320 DOI: 10.1111/apt.12365] 25 Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. Gastroenterol Res Pract 2014; 2014: 872725 [PMID: 24799893 DOI: 10.1155/2014/872725] 26 Hansen R, Russell RK, Reiff C, Louis P, McIntosh F, Berry SH, Mukhopadhya I, Bisset WM, Barclay AR, Bishop J, Flynn DM, McGrogan P, Loganathan S, Mahdi G, Flint HJ, El-Omar EM, Hold GL. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn’s but not in ulcerative colitis. Am J Gastroenterol 2012; 107: 1913-1922 [PMID: 23044767 DOI: 10.1038/ajg.2012.335] 27 Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53: 169-174 [PMID: 17520365 DOI: 10.1007/s10620-007-9839-8] 28 Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-1801 [PMID: 21820992 DOI: 10.1053/ j.gastro.2011.07.043] 29 Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, Sokol H, Coffin B, Sabaté JM. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 513-520, e246-e247 [PMID: 22356587 DOI: 10.1111/j.1365-2982.2012.01893.x] 30 Lopez-Siles M, Martinez-Medina M, Busquets D , S a b a t - M i r M , D u n c a n S H , F l i n t H J , Aldeguer X, Garcia-Gil LJ. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable Bowel Syndrome and Inflammatory Bowel Disease phenotypes. Int J Med Microbiol 2014; 304: 464-475 [PMID: 24713205 DOI: 10.1016/ j.ijmm.2014.02.009] 31 Soldi S, Vasileiadis S, Uggeri F, Campanale M, Morelli L, Fogli MV, Calanni F, Grimaldi M, Gasbarrini A. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol 2015; 8: 309-325 [PMID: 26673000 DOI: 10.2147/CEG.S89999] 32 Miquel S, Martín R, Lashermes A, Gillet M, Meleine M, Gelot A, Eschalier A, Ardid D, Bermúdez-Humarán LG, Sokol H, Thomas M, Theodorou V, Langella P, Carvalho FA. Anti￾nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Sci Rep 2016; 6: 19399 [PMID: 26775847 DOI: 10.1038/ srep19399] 33 Lopez-Siles M, Martinez-Medina M, Surís-Valls R, Aldeguer X, Sabat-Mir M, Duncan SH, Flint HJ, Garcia-Gil LJ. Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer. Inflamm Bowel Dis 2016; 22: 28-41 [PMID: 26595550 DOI: 10.1097/MIB.0000000000000590] 34 Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol 2008; 23: 1298-1303 [PMID: 18624900 DOI: 10.1111/ j.1440-1746.2008.05490.x] 35 Scanlan PD, Shanahan F, Clune Y, Collins JK, O’ Sullivan GC, O’Riordan M, Holmes E, Wang Y, Marchesi JR. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol 2008; 10: 789-798 [PMID: 18237311 DOI: 10.1111/j.1462-2920.2007.01503.x] 36 Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Tran Van Nhieu J, Furet JP. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011; 6: e16393 [PMID: 21297998 DOI: 10.1371/journal.pone.0016393] 37 De Palma G, Nadal I, Medina M, Donat E, Ribes￾Koninckx C, Calabuig M, Sanz Y. Intestinal dysbiosis and reduced immunoglobulin￾coated bacteria associated with coeliac disease in children. BMC Microbiol 2010; 10: 63 [PMID: 20181275 DOI: 10.1186/1471-2180-10-63] 38 Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 2008; 135: 568-579 [PMID: 18570896 DOI: 10.1053/ j.gastro.2008.04.017] 39 Swidsinski A, Dörffel Y, Loening-Baucke V, Theissig F, Rückert JC, Ismail M, Rau WA, Gaschler D, Weizenegger M, Kühn S, Schilling J, Dörffel WV. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/ necrophorum. Gut 2011; 60: 34-40 [PMID: 19926616 DOI: 10.1136/gut.2009.191320] 编辑:马亚娟 电编:李瑞芳 ■同行评价 F. prausnitzii 作 为人类最丰富的 肠 道 共 生 菌 之 一, 其在肠道疾 病中所起的作用 越来越引起人们 的重视. 本文对F. prausnitzii的作用 机制、抗炎有效 成分以及与肠道 疾病的关系的研 究进展做了较为 系统的综述, 有 理论和实用价值